Home > Oncology > Cemiplimab boosts survival in recurrent cervical cancer

Cemiplimab boosts survival in recurrent cervical cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The New England Journal of Medicine
Reuters Health - 09/02/2022 -Treating recurrent cervical cancer with cemiplimab reduces the risk of death by 31% compared with single-agent chemotherapy, according to results from the EMPOWER-Cervical 1 trial. Survival was 12.0 months versus 8.5 months among women who received the investigator's choice of chemotherapy (P<0.001), researchers report in the New England Journal of Medicine. "The survival benefit with cemiplimab was observed in patients with squamous-cell carcinoma and in those with adenocarcinoma or adenosquamous carcinoma," Dr. Krishnansu Tewari of the University of California, Irvine, and colleagues write. The median progression-free survival among the 304 patients who received cemiplimab was 2.8 months versus 2.9 months for the 304 volunteers in the control group, a non-significant difference. An objective response was seen in 18% of cemiplimab patients with PD-L1 expression greater than or equal to 1%, 11% with PD-L1 expression of l...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on